Launch of 2nd NDA Bortezomib for injection3.5mg/1.4ml in US

Regulatory product approvalExport order in hard currencyBusiness Updates View source PDF Explain this filing

SHILPAMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.2%Reaction day

₹324.00

prior close

₹340.70

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+1.0%+3.1% vs market

Pharmaceuticals peers, median of 147sector+2.3%+1.9% vs sector

On the reaction day the stock moved 3.1 pts more than Nifty Microcap 250 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

-0.4

15m

-0.2

30m

-0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.2+1.0+3.1+2.3+1.9

Next day

-2.5-2.6+0.1-0.6-1.9

-6.8-6.9+0.1-4.6-2.1

-0.8-4.6+3.8-3.1+2.3

-6.3-5.8-0.5-4.0-2.3

-1.5-2.6+1.1-2.1+0.5

+1.4+1.4+0.0+1.0+0.4

15d

+2.4+2.0+0.4+2.2+0.2

+3.6+1.2+2.4+1.3+2.3

+34.9+11.7+23.2+6.4+28.5

+37.3+15.2+22.1+7.1+30.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Shilpa Medicare has received USFDA approval and is launching its second NDA (New Drug Application) for Bortezomib injection at the 3.5mg/1.4ml strength in the US market. Bortezomib is a key chemotherapy drug used to treat multiple myeloma and mantle cell lymphoma. This is the company's second approved Bortezomib product, strengthening its oncology injectable portfolio in the world's largest pharmaceutical market. The launch positions Shilpa to capture additional share in a high-value, niche oncology segment with limited generic competition.

Likely market impact

Positive for the stock — a new product launch in the US, a hard-currency export market, broadens the company's approved oncology range and supports future revenue growth from its CDMO/finished dosage business.